Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders

Fiona M. Ross, Hervé Avet-Loiseau, Geneviève Ameye, Norma C. Gutiérrez, Peter Liebisch, Sheila O'Connor, Klara Dalva, Sonia Fabris, Adele M. Testi, Marie Jarosova, Clare Hodkinson, Anna Collin, Gitte Kerndrup, Petr Kuglik, Dariusz Ladon, Paolo Bernasconi, Brigitte Maes, Zuzana Zemanova, Kyra Michalova, Lucienne MichauKai Neben, N. Emil U Hermansen, Katrina Rack, Alberto Rocci, Rebecca Protheroe, Laura Chiecchio, Hélène A. Poirel, Pieter Sonneveld, Mette Nyegaard, Hans E. Johnsen

Research output: Contribution to journalArticle

Abstract

The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10% for fusion or breakapart probes, 20% for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance.

Original languageEnglish
Pages (from-to)1272-1277
Number of pages6
JournalHaematologica
Volume97
Issue number8
DOIs
Publication statusPublished - Aug 1 2012

Fingerprint

Interphase
Multiple Myeloma
Quality Control
Databases
Education
Group Processes
Plasma Cells
Fluorescence In Situ Hybridization
Consensus
Recurrence

Keywords

  • Cytogenetic
  • Interphase FISH
  • Myeloma
  • Recommendation

ASJC Scopus subject areas

  • Hematology

Cite this

Ross, F. M., Avet-Loiseau, H., Ameye, G., Gutiérrez, N. C., Liebisch, P., O'Connor, S., ... Johnsen, H. E. (2012). Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica, 97(8), 1272-1277. https://doi.org/10.3324/haematol.2011.056176

Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. / Ross, Fiona M.; Avet-Loiseau, Hervé; Ameye, Geneviève; Gutiérrez, Norma C.; Liebisch, Peter; O'Connor, Sheila; Dalva, Klara; Fabris, Sonia; Testi, Adele M.; Jarosova, Marie; Hodkinson, Clare; Collin, Anna; Kerndrup, Gitte; Kuglik, Petr; Ladon, Dariusz; Bernasconi, Paolo; Maes, Brigitte; Zemanova, Zuzana; Michalova, Kyra; Michau, Lucienne; Neben, Kai; Hermansen, N. Emil U; Rack, Katrina; Rocci, Alberto; Protheroe, Rebecca; Chiecchio, Laura; Poirel, Hélène A.; Sonneveld, Pieter; Nyegaard, Mette; Johnsen, Hans E.

In: Haematologica, Vol. 97, No. 8, 01.08.2012, p. 1272-1277.

Research output: Contribution to journalArticle

Ross, FM, Avet-Loiseau, H, Ameye, G, Gutiérrez, NC, Liebisch, P, O'Connor, S, Dalva, K, Fabris, S, Testi, AM, Jarosova, M, Hodkinson, C, Collin, A, Kerndrup, G, Kuglik, P, Ladon, D, Bernasconi, P, Maes, B, Zemanova, Z, Michalova, K, Michau, L, Neben, K, Hermansen, NEU, Rack, K, Rocci, A, Protheroe, R, Chiecchio, L, Poirel, HA, Sonneveld, P, Nyegaard, M & Johnsen, HE 2012, 'Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders', Haematologica, vol. 97, no. 8, pp. 1272-1277. https://doi.org/10.3324/haematol.2011.056176
Ross FM, Avet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O'Connor S et al. Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012 Aug 1;97(8):1272-1277. https://doi.org/10.3324/haematol.2011.056176
Ross, Fiona M. ; Avet-Loiseau, Hervé ; Ameye, Geneviève ; Gutiérrez, Norma C. ; Liebisch, Peter ; O'Connor, Sheila ; Dalva, Klara ; Fabris, Sonia ; Testi, Adele M. ; Jarosova, Marie ; Hodkinson, Clare ; Collin, Anna ; Kerndrup, Gitte ; Kuglik, Petr ; Ladon, Dariusz ; Bernasconi, Paolo ; Maes, Brigitte ; Zemanova, Zuzana ; Michalova, Kyra ; Michau, Lucienne ; Neben, Kai ; Hermansen, N. Emil U ; Rack, Katrina ; Rocci, Alberto ; Protheroe, Rebecca ; Chiecchio, Laura ; Poirel, Hélène A. ; Sonneveld, Pieter ; Nyegaard, Mette ; Johnsen, Hans E. / Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. In: Haematologica. 2012 ; Vol. 97, No. 8. pp. 1272-1277.
@article{f9e4c40db9c34c5d92a5eb78c1653f0d,
title = "Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders",
abstract = "The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10{\%} for fusion or breakapart probes, 20{\%} for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance.",
keywords = "Cytogenetic, Interphase FISH, Myeloma, Recommendation",
author = "Ross, {Fiona M.} and Herv{\'e} Avet-Loiseau and Genevi{\`e}ve Ameye and Guti{\'e}rrez, {Norma C.} and Peter Liebisch and Sheila O'Connor and Klara Dalva and Sonia Fabris and Testi, {Adele M.} and Marie Jarosova and Clare Hodkinson and Anna Collin and Gitte Kerndrup and Petr Kuglik and Dariusz Ladon and Paolo Bernasconi and Brigitte Maes and Zuzana Zemanova and Kyra Michalova and Lucienne Michau and Kai Neben and Hermansen, {N. Emil U} and Katrina Rack and Alberto Rocci and Rebecca Protheroe and Laura Chiecchio and Poirel, {H{\'e}l{\`e}ne A.} and Pieter Sonneveld and Mette Nyegaard and Johnsen, {Hans E.}",
year = "2012",
month = "8",
day = "1",
doi = "10.3324/haematol.2011.056176",
language = "English",
volume = "97",
pages = "1272--1277",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders

AU - Ross, Fiona M.

AU - Avet-Loiseau, Hervé

AU - Ameye, Geneviève

AU - Gutiérrez, Norma C.

AU - Liebisch, Peter

AU - O'Connor, Sheila

AU - Dalva, Klara

AU - Fabris, Sonia

AU - Testi, Adele M.

AU - Jarosova, Marie

AU - Hodkinson, Clare

AU - Collin, Anna

AU - Kerndrup, Gitte

AU - Kuglik, Petr

AU - Ladon, Dariusz

AU - Bernasconi, Paolo

AU - Maes, Brigitte

AU - Zemanova, Zuzana

AU - Michalova, Kyra

AU - Michau, Lucienne

AU - Neben, Kai

AU - Hermansen, N. Emil U

AU - Rack, Katrina

AU - Rocci, Alberto

AU - Protheroe, Rebecca

AU - Chiecchio, Laura

AU - Poirel, Hélène A.

AU - Sonneveld, Pieter

AU - Nyegaard, Mette

AU - Johnsen, Hans E.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10% for fusion or breakapart probes, 20% for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance.

AB - The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10% for fusion or breakapart probes, 20% for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance.

KW - Cytogenetic

KW - Interphase FISH

KW - Myeloma

KW - Recommendation

UR - http://www.scopus.com/inward/record.url?scp=84864758817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864758817&partnerID=8YFLogxK

U2 - 10.3324/haematol.2011.056176

DO - 10.3324/haematol.2011.056176

M3 - Article

C2 - 22371180

AN - SCOPUS:84864758817

VL - 97

SP - 1272

EP - 1277

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -